2-Hydroxy-5-(2-nitrovinyl)benzoic acid
2-Hydroxy-5-(2-nitrovinyl) benzoic acid (SANA) is an orally active pleiotropic anti-inflammatory metabolic modulator. 2-Hydroxy-5-(2-nitrovinyl) benzoic acid inhibits NF-κB, activates Nrf2/Keap1 and AMPK, suppresses inflammasome activity, induces thermogenesis, reverses insulin resistance and alleviates skin graft rejection. 2-Hydroxy-5-(2-nitrovinyl) benzoic acid can be used in research related to obesity, glucose intolerance, skin graft rejection and insulin resistance.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 42571-07-3
- 分子式: C9H7NO5
- 分子量:209.16
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
IL-6 |
IL-1β |
体外実験
2-Hydroxy-5-(2-nitrovinyl) benzoic acid (0.1 mM; 2 h) potently inhibits LPS (HY-D1056)-induced nuclear translocation of NF-κB/p65 in THP-1 macrophages[1].
2-Hydroxy-5-(2-nitrovinyl) benzoic acid (100-200 μM; 5 h) inhibits NF-κB-dependent gene expression of IL-6, TNF-α and MCP-1 in LPS-induced differentiated THP-1 macrophages[1].
2-Hydroxy-5-(2-nitrovinyl) benzoic acid (50-200 μM; 18 h) inhibits LPS-induced NF-κB-dependent IL-6 secretion in RAW 264.7 macrophages in a dose-dependent manner[1].
2-Hydroxy-5-(2-nitrovinyl) benzoic acid (0.1 mM; 5 h) induces Nrf2/Keap1-dependent expression of HO-1, GCLM and NQO1 genes in human hepatoma Hep G2 cells[1].
When co-administered with the initial LPS signal, 2-Hydroxy-5-(2-nitrovinyl) benzoic acid (0.05-0.25 mM; 3.75 h) dose-dependently inhibits inflammasome-mediated IL-1β secretion in differentiated THP-1 macrophages without reducing cell viability[1].
2-Hydroxy-5-(2-nitrovinyl) benzoic acid (0.05-0.25 mM; 3.75 h) exerts a dose-dependent inhibitory effect on inflammasome-mediated IL-1β secretion in differentiated THP-1 macrophages without reducing cell viability when acting in conjunction with a second ATP signal[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:THP-1 macrophages
-
Concentration:0.1 mM
-
Incubation Time:2 h (pre-incubation)
-
Result:Prevented LPS-induced nuclear translocation of NF-κB/p65, with equivalent effect to 1 mM salicylic acid indicating greater potency.
-
Cell Line:differentiated THP-1 macrophages
-
Concentration:100-200 μM
-
Incubation Time:2 h (pre-incubation); 3 h (LPS stimulation)
-
Result:Inhibited LPS-induced NF-κB-dependent expression of IL-6, TNF-α, and MCP-1 genes, while salicylic acid at the same concentrations showed no inhibitory activity.
-
Cell Line:murine RAW 264.7 macrophages
-
Concentration:50-200 μM
-
Incubation Time:2 h (pre-incubation); 16 h (LPS stimulation)
-
Result:Dose-dependently inhibited LPS-induced IL-6 secretion, with significant inhibition observed at all tested concentrations (p < 0.05 compared to LPS-DMSO control), and was more potent than 1 mM salicylic acid.
-
Cell Line:Hep G2 human liver cells
-
Concentration:0.1 mM
-
Incubation Time:5 h
-
Result:Induced expression of Nrf2/Keap1-dependent phase two enzyme genes (HO-1, GCLM, NQO1), while salicylic acid at 0.2 mM and 5 mM did not induce such expression.
-
Cell Line:differentiated THP-1 macrophages
-
Concentration:0.05-0.25 mM
-
Incubation Time:3 h (co-incubation with LPS); 45 min (ATP stimulation)
-
Result:Dose-dependently inhibited LPS/ATP-induced IL-1β secretion, with no reduction in cell viability observed; salicylic acid at 0.25 mM did not inhibit IL-1β secretion.
-
Cell Line:differentiated THP-1 macrophages
-
Concentration:0.05-0.25 mM
-
Incubation Time:3 h (LPS stimulation); 45 min (co-incubation with ATP)
-
Result:Dose-dependently inhibited LPS/ATP-induced IL-1β secretion, with no reduction in cell viability observed; salicylic acid at 0.25 mM did not inhibit IL-1β secretion.
体内実験
SANA (100 mg/kg; i.p.; single administration) significantly inhibits LPS-induced peritoneal IL-1β secretion in mice[1].
SANA (100 mg/kg; p.o.; once daily; for 16 consecutive days) significantly prolongs the survival time of skin allografts in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6[1]
-
Dosage:200 mg/kg (p.o.); 100-400 mg/kg (i.p.)
-
Administration:p.o. (gavage; single dose); i.p. (single dose)
-
Result:Increased pAMPK levels in mouse liver compared to PBS control.
Increased pAMPK levels in mouse liver, with higher doses showing greater elevation.
Increased pAMPK levels relative to control.
-
Animal Model:C57BL/6[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; single dose (administered 2 hours pre-LPS)
-
Result:Reduced LPS-induced IL-1β secretion into the peritoneum, with a statistically significant difference compared to LPS + buffer control.
-
Animal Model:C57BL/6 (female recipients, male donors)[1]
-
Dosage:100 mg/kg
-
Administration:p.o. (gavage); daily; 16 days total (1 pre-transplant day + 15 post-transplant days)
-
Result:Prolonged skin allograft survival compared to vehicle control.
Prolonged allograft survival significantly longer than in salicylic acid-treated mice.
化学情報
-
CAS 番号 42571-07-3
-
分子量 209.16
-
分子式 C9H7NO5
-
SMILES
O=C(C1=CC(/C=C/[N+]([O-])=O)=CC=C1O)O
-
別名
SANA
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)